Press-release for stocks related to trial

| Email alert Add to watchlist
atile-002 versamune biotech hpv cancer key trial

STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
Published: 2024-04-17 (Crawled : 11:00) - globenewswire.com
CTSO | $0.81 1.0% 2.05% 95K

| -0.98% | O: -0.99% H: 0.0% C: 0.0%
association presentation for meeting trial results

New Topline Efficacy Data from the enVVeno Medical VenoValve® Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
Published: 2024-04-16 (Crawled : 15:00) - hancockjaffe.com
NVNO | $4.91 6.28% 5.52% 72K

| -0.2% | O: -1.22% H: 0.0% C: -2.06%
venovalve symposium topline medical trial

New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
NVNO | $4.91 6.28% 5.52% 72K

| -0.2% | O: -1.22% H: 0.0% C: -2.06%
symposium topline medical trial

SMART trial one-year data demonstrates Medtronic Evolut™ TAVR platform as optimal treatment for severe aortic stenosis in patients with small annulus, which is primarily women
Published: 2024-04-07 (Crawled : 16:20) - prnewswire.com
MDT | $80.57 1.37% 0.0% 150

| Email alert Add to watchlist
EW | $86.96 1.19% 0.0% 2M

| Email alert Add to watchlist
treatment for women smart trial platform

Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
Published: 2024-03-26 (Crawled : 06:00) - globenewswire.com
DVAX | $11.84 0.34% 0.34% 3

| -5.28% | O: 0.72% H: 0.4% C: -1.75%
candidate vaccine valneva trial

ROSEN, LEADING TRIAL ATTORNEYS, Encourages iRobot Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - IRBT
Published: 2024-03-20 (Crawled : 20:00) - prnewswire.com
BTAFF | $30.26 8.07% 44.6% 0

Consumer Non-Durables

| -3.04% | O: -3.87% H: 0.0% C: -1.14%
BTI | $29.41 1.24% 0.17% 5.4M

Consumer Non-Durables

| -5.07% | O: -2.13% H: 0.26% C: -0.56%
IRBT | $6.74 -6.91% -7.34% 4.4K

Consumer Durables

| -18.02% | O: 0.81% H: 2.88% C: -3.11%
AMZN S | $177.23 1.49% 2.0% 28M

Retail Trade

| -0.52% | O: 1.03% H: 0.79% C: -1.02%
corporation deadline trial

Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients
Published: 2024-03-19 (Crawled : 15:00) - biospace.com/
CERS | $1.69 0.6% 1.18% 550K

| -9.14% | O: 12.9% H: 5.71% C: -2.86%
corporation positive blood system topline trial cardiovascular results

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Palo Alto Networks, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PANW
Published: 2024-03-12 (Crawled : 20:00) - prnewswire.com
XPOF | $12.7 -3.42% 0.0% 1M

| -16.78% | O: 0.59% H: 2.21% C: -1.89%
PANW | $281.68 1.43% 1.4% 6.7K

| -1.07% | O: 0.31% H: 2.51% C: 1.58%
IRBT | $6.74 -6.91% -7.34% 4.4K

Consumer Durables

| -28.5% | O: -0.41% H: 4.58% C: -0.31%
deadline trial

Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting
Published: 2024-03-11 (Crawled : 12:30) - globenewswire.com
DERM | $3.54 1.72% 1.42% 38K

| 2.61% | O: -1.45% H: 0.88% C: -0.88%
FBIO | $1.75 0.57% 150K

| -16.67% | O: -0.48% H: 2.87% C: -4.31%
dfd-29 presentation corporation meeting impact medical trial

Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting
Published: 2024-03-06 (Crawled : 14:30) - biospace.com/
NVNO | $4.91 6.28% 5.52% 72K

| -23.4% | O: 2.96% H: 3.48% C: -9.7%
enous2024 positive topline meeting trial today

Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve® Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting
Published: 2024-03-06 (Crawled : 14:30) - hancockjaffe.com
NVNO | $4.91 6.28% 5.52% 72K

| -23.4% | O: 2.96% H: 3.48% C: -9.7%
enous2024 venovalve positive topline meeting trial today

Insulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
Published: 2024-03-05 (Crawled : 12:30) - biospace.com/
PODD | $164.42 -1.1% -1.09% 680K

| -2.03% | O: 1.89% H: 0.02% C: -4.13%
omnipod first conference international trial advanced diabetes results

Pulmonx Announces Treatment of the First Patient with the AeriSeal® System in CONVERT II Pivotal Trial
Published: 2024-02-26 (Crawled : 15:30) - biospace.com/
LUNG | $7.4 -1.47% -1.62% 0

| -31.54% | O: -0.65% H: 3.35% C: -3.26%
aeriseal first treatment system trial

Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024
Published: 2024-02-20 (Crawled : 14:00) - biospace.com/
NVNO | $4.91 6.28% 5.52% 72K

| -2.19% | O: 2.59% H: 15.53% C: 7.18%
enous2024 topline meeting medical trial

MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®
Published: 2024-02-15 (Crawled : 11:00) - globenewswire.com
MNKD | $4.11 -1.68% -1.46% 1.8M

| 14.17% | O: 0.56% H: 3.31% C: 2.49%
afrezza trial diabetes

MRCY DEADLINE ALERT: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Mercury Systems, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important February 12 Deadline in Securities Class Action - MRCY
Published: 2024-02-03 (Crawled : 20:20) - prnewswire.com
MRCY | News | $27.52 -1.64% -1.63% 1

| Email alert Add to watchlist
EGRX | $4.55 -1.3% -1.32% 280K

| Email alert Add to watchlist
ON | $60.65 -0.1% -0.07% 4.9K

| Email alert Add to watchlist
deadline mercury trial

4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden
Published: 2024-01-29 (Crawled : 13:00) - globenewswire.com
FDMT M | $26.39 4.52% 4.46% 0

| 50.8% | O: 2.46% H: 1.28% C: 0.5%
disease prism treatment trial

ROSEN, NATIONAL TRIAL COUNSEL, Encourages Mercury Systems, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - MRCY
Published: 2024-01-27 (Crawled : 20:20) - prnewswire.com
BROG | $1.11 -0.89% -5.66% 19K

Finance

| Email alert Add to watchlist
MRCY | News | $27.52 -1.64% -1.63% 1

| Email alert Add to watchlist
ON | $60.65 -0.1% -0.07% 4.9K

| Email alert Add to watchlist
deadline mercury trial

Global Pharma Clinical Trial Services Market Report 2024: Harnessing AI and Real-World Data for Clinical Trial Innovation and Services - Long-term Forecast to 2034
Published: 2024-01-25 (Crawled : 17:00) - prnewswire.com
TMO | News | $548.38 0.66% 0.86% 1.2M

| -0.09% | O: -1.03% H: 0.84% C: -0.92%
LH M | $203.07 0.79% 0.56% 41

Health Services

| -9.08% | O: 0.78% H: 0.76% C: 0.69%
ICLR | News | $297.93 3.37% 3.33% 780K

| 12.97% | O: 0.76% H: 0.71% C: -0.09%
pharma services report innovation global trial market

← Previous
1
2
3
4
5
6
7
8
9
…
25
26
Next →

Gainers vs Losers

73%

27%

Top 10 Gainers

AGBA | $2.5 100.0% 58.33% 200M

Finance

EDBL | News | $6.26 66.49% 48.56% 270K

MLEC | $2.47 76.43% 38.05% 460K

n/a

PALI | $4.93 4.67% 25.83% 2.1M

SILO | $1.99 0.71% 20.64% 1.8M

Finance and Insurance

NNVC | $1.12 1.82% 19.64% 2.5K

CANG | $1.34 -4.29% 14.93% 120K

Technology Services

AZTR 4 | $0.195 13.85% 42K

n/a

TOVX | News | $0.411 -1.01% 12.9% 230K

IBRX | $4.94 -6.26% 10.83% 4.5M